https://data.who.int/dashboards/covid19/summary?n=o Kummallista , että BA.3 linja antaa nyt jonkin variantin. Katson sitä erikseen.
The objective of this report is to provide a comprehensive overview of reported data on SARS-CoV-2 viral activity and the burden of the COVID-19 on the human population over the past seven to 28 days from the last reporting date. This overview and other sections are based on data submitted by Member States' Ministries of Health to the World Health Organization (WHO) through various surveillance systems, as well as updates from the health ministries' websites of the Member States. Information in this overview should be interpreted considering the data limitations detailed beneath each section.
Circulation
SARS-CoV-2 activity: Last 7 days
In the week of 29 December 2025 to 4 January 2026, a total of 75,393 samples were tested for SARS-CoV-2, the virus that causes COVID-19, across 66 countries (Table 1.1, 1.2). WHO collects this data from a global network of sentinel and systematic virologic surveillance sites. Out of these, 3,363 (4.5%) samples tested positive for the virus. During this period, SARS-CoV-2 activity was low and stable globally, with variations observed across some WHO regions. Elevated activity or increases were reported in countries in Temperate South America, Northern and Eastern Europe, and South-East and Eastern Asia.
n the 28-day period from 08 December 2025 to 04 January 2026, 65 countries across three WHO regions reported new COVID-19 cases. During this 28-day period, a total of 49,665 new cases were reported, which is a decrease compared to the 71,224 new cases reported from 88 countries in the previous 28-day period (Table 2.1, 2.2). Overall, 12 countries from the Americas and Europe showed an increase in new cases of over 10%.
SARS-CoV-2 variant circulation: 30 November to 28 December 2025
WHO is currently tracking several SARS-CoV-2 variants:
- Variants of Interest: JN.1
- Variants Under Monitoring: XFG, NB.1.8.1, KP.3.1.1, BA.3.2, and LP.8.1
At the global level, the most prevalent variant, XFG, accounted for 75% of all submitted sequences in the week ending on 28 December 2025 which is an increase from 68% in the week ending on 30 November 2025. Within the same reporting period, NB.1.8.1 accounted for 9% of all submitted sequences, a decrease from 15%, and BA.3.2 remained stable, accounting for 3% of all submitted sequences (Table 3).
During this reporting period, all other variants showed a decreasing or stable trend. Available evidence suggests that XFG, NB.1.8.1, and BA.3.2 do not pose additional public health risks relative to other currently circulating SARS-CoV-2 variants.
At the regional level, within the reporting period from week ending 30 November to 28 December 2025, XFG increased in the Western Pacific Region and remained stable in the European Region and in the Americas, which were the regions with sufficient data. NB.1.8.1 increased in the European Region and remained stable in the Americas, and BA.3.2 increased in the European Region.
Deaths: Last 28 days
In the 28-day period from 08 December 2025 to 04 January 2026, 39 countries across three WHO regions reported new COVID-19 deaths. During this 28-day period, a total of 1,286 new deaths were reported (Table 5.1), which is an increase compared to the 1,044 new deaths reported from 39 countries in the previous 28-day period (Table 5.2). Thirteen countries from the Americas and Europe showed an increase in new deaths of over 10%. In December 2025, 91% of reported deaths with age information occurred in the population aged 65 and over.
Inga kommentarer:
Skicka en kommentar